ZyVersa Therapeutics, Inc., a clinical-stage biopharmaceutical company, announced the scheduling of its 2024 Annual Meeting of Stockholders to be held virtually on October 29, 2024. The meeting will invite stockholders to elect one Class II director nominee, Dr. Min Chul Park, for a three-year term, ratify the selection of Marcum LLP as the independent registered public accounting firm for the year ending December 31, 2024, approve an amendment to increase the number of shares reserved under the 2022 Omnibus Equity Incentive Plan, and approve the issuance of shares upon the exercise of certain warrants in accordance with Nasdaq Listing Rule 5635(d). The record date for the Annual Meeting is set for September 4, 2024, with only stockholders of record at the close of business on that date or their proxies eligible to vote. The company emphasizes the importance of stockholder participation and encourages the submission of proxies prior to the meeting.

ZyVersa Therapeutics, Inc., a clinical-stage biopharmaceutical company, announced the scheduling of its 2024 Annual Meeting of Stockholders to be held virtually on October 29, 2024. The meeting will invite stockholders to elect one Class II director nominee, Dr. Min Chul Park, for a three-year term, ratify the selection of Marcum LLP as the independent registered public accounting firm for the year ending December 31, 2024, approve an amendment to increase the number of shares reserved under the 2022 Omnibus Equity Incentive Plan, and approve the issuance of shares upon the exercise of certain warrants in accordance with Nasdaq Listing Rule 5635(d). The record date for the Annual Meeting is set for September 4, 2024, with only stockholders of record at the close of business on that date or their proxies eligible to vote. The company emphasizes the importance of stockholder participation and encourages the submission of proxies prior to the meeting.